Lactobacillus johnsonii N6.2

Cell therapyexperimental

Clinical trial activity

7 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Aug 1, 2015 (NCT02349360)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • microbiotaTissue restoration

    microbiota tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • l. johnsonii n6.2

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07191405N/ASep 18, 2025Zhejiang University
NCT06866990N/AMar 31, 2025Zhejiang University
NCT06823323N/AMar 1, 2025Chinese Academy of Medical Sciences, Wenzhou Medical University, Zhejiang University
NCT03961854Phase 1/Phase 2 (Phase 2)Jul 31, 2019Juvenile Diabetes Research Foundation, University of Florida
NCT03961347Phase 1/Phase 2 (Phase 2)Jul 31, 2019National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Florida
NCT03880760N/AAug 1, 2018China Medical University
NCT02349360N/AAug 1, 2015Juvenile Diabetes Research Foundation, University of Florida
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of FloridaAcademic/Hospital3322015
Zhejiang UniversityAcademic/Hospital3312025
Juvenile Diabetes Research FoundationAcademic/Hospital2022015
China Medical UniversityAcademic/Hospital1112018
Chinese Academy of Medical SciencesAcademic/Hospital1012025
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government1012019
Wenzhou Medical UniversityAcademic/Hospital1012025
7 organizations
Page 1 / 1